ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Human trial data of oral small molecule PD-1/PD-L1 inhibitors were first released
December 02, 2021Recently, Incyte of the United States reported the Phase I clinical data of oral small molecule PD-L1 inhibitor INCB086550 in Journal for ImmunoTherapy of Cancer. -
Adlai Nortye Announces First Patient Dosed in Phase I Clinical Trial of the orally available, small-molecule PD-L1 inhibitor AN4005 for Advanced Tumors
January 06, 2022Adlai Nortye Ltd. ("Adlai Nortye"), a clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies, announced that the first patient was dosed in the Phase I clinical trial... -
Maxinovel's Orally Active PD-L1 Inhibitor Demonstrating Similar Efficacy to PD-L1 Antibody Durvalumab
April 21, 2019Maxinovel Pharmaceuticals, Inc. presented in the 2019 AACR the head to head comparison of its orally active small ……
Pharma Sources Insight January 2025
